Glycoprotein IIb/IIIa PET/CT in Various GPIIb/IIIa-Related Disease

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07813559

Enrollment

500

Registered

2026-09-10

Start date

2026-09-01

Completion date

2031-09-01

Last updated

2026-09-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thrombi, Thrombus, Thrombus, Brain

Keywords

PET/CT, thrombus, thrombi, GPIIb/IIIa receptors

Brief summary

In the field of diagnosing Thrombi diseases, it is now a well established practice to inject positron-emitting tracers into the human body. These tracers bind to specific target proteins, allowing their distribution to be visualized via PET imaging. Currently, several research groups worldwide are engaged in developing and clinically validating their own GPIIb/IIIa imaging agents.

Detailed description

This clinical research project aims to visualize abnormal tau pathology in the living human brain using \[18F/68Ga\]GP1 PET imaging. \[18F/68Ga\]GP1 is a small molcule-based tracer that offers stronger binding affinity to GPIIb/IIIa. The study primarily focuses on evaluating the safety and diagnostic efficacy of \[18F/68Ga\]GP1 PET imaging in human subjects.

Interventions

DIAGNOSTIC_TEST18F/68Ga-GP1

Each subject receive a single intravenous injection of 18F/68Ga-GP1, and undergo PET/ CT or MRI imaging within the specificed time.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Yes

Inclusion criteria

* (i) adult patients (aged 18 years or order); (ii) patients with suspected or new diagnosed or previously treated thrombi (supporting evidence may include MRI, CT, tumor markers and pathology report); (iii) patients who had scheduled GPIIb/IIIa PET/CT scan; (iv) patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion criteria

* (i) patients with non-thrombi lesions; (ii) patients with pregnancy; (iii) the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Design outcomes

Primary

Measure	Time frame	Description
Standardized uptake value (SUV)	30 days	Standardized uptake value (SUV) of 18F/68Ga-GP1 for each target lesion of subject or suspected thrombi.

Secondary

Measure	Time frame	Description
Diagnostic efficacy	30 days	The sensitivity, specificity and accuracy of GPIIb/IIIa PET/CT were calculated.

Countries

China

Contacts

CONTACTHaonan Yu, MD

dreamadam@126.com+8613821000597

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Sep 11, 2026